| 1. |
Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol, 2016, 34(12): 1350-1357.
|
| 2. |
Yu J, Huang C, Sun Y, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: The CLASS-01 randomized clinical trial. JAMA, 2019, 321(20): 1983-1992.
|
| 3. |
Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016, 27(suppl 5): v38-v49.
|
| 4. |
Ajani JA, D’Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2016, 14(10): 1286-1312.
|
| 5. |
日本胃癌學會. 胃癌治療ガイドライン. 第5版. 東京: 金原出版株式會社, 2018.
|
| 6. |
Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond), 2019, 39(1): 10.
|
| 7. |
中華人民共和國國家衛生健康委員會. 胃癌診療規范(2018 年版). http://www.nhc.gov.cn/.
|
| 8. |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1): 11-20.
|
| 9. |
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial. J Clin Oncol, 2011, 29(13): 1715-1721.
|
| 10. |
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012, 366(22): 2074-2084.
|
| 11. |
Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol, 2016, 17(12): 1697-1708.
|
| 12. |
Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol, 2018, 19(5): 616-628.
|
| 13. |
Kodera Y. Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today, 2017, 47(8): 899-907.
|
| 14. |
Kurokawa Y, Sasako M. The Asian perspective on the surgical and adjuvant management of esophagogastric cancer. Surg Oncol Clin N Am, 2017, 26(2): 213-224.
|
| 15. |
Springfeld C, Wiecha C, Kunzmann R, et al. Influence of different neoadjuvant chemotherapy regimens on response, prognosis, and complication rate in patients with esophagogastric adeno-carcinoma. Ann Surg Oncol, 2015, 22 Suppl 3: S905-S914.
|
| 16. |
Feng D, Leong M, Li T, et al. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. World J Surg Oncol, 2015, 13: 11.
|
| 17. |
Li Z, Shan F, Wang Y, et al. Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: safety and short-term oncologic results. Surg Endosc, 2016, 30(10): 4265-4271.
|
| 18. |
Yoshikawa T, Sasako M, Yamamoto S, et al. Phase Ⅱ study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg, 2009, 96(9): 1015-1022.
|
| 19. |
Iwasaki Y, Sasako M, Yamamoto S, et al. Phase Ⅱ study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol, 2013, 107(7): 741-745.
|
| 20. |
Ito S, Sano T, Mizusawa J, et al. A phase Ⅱ study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer, 2017, 20(2): 322-331.
|
| 21. |
Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol, 2017, 3(9): 1197-1203.
|
1/5
WeChat